Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionMission Wealth Management, Lp
Latest Disclosed Ownership2,205 shares
Latest Disclosed Value $ 290,487
Mission Wealth Management, Lp reports 1.33% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 15, 2026 - Mission Wealth Management, Lp filed a 13F-HR form disclosing ownership of 2,205 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $290,487 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 5, 2026 disclosing 2,176 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 1.33% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,205 29 1.33 290 -5.84 0.0060
2026-02-05 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,176 192 9.68 309 10.79 0.0062
2025-11-04 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,984 69 3.60 279 15.83 0.0055
2025-08-05 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,915 -295 -13.35 241 -1.64 0.0051
2025-04-17 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,210 400 22.10 244 -1.21 0.0060
2025-02-06 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,810 1,810 247 0.0058
2024-10-31 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -1,725 -100.00 0 -100.00
2024-08-05 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,725 0 0.00 237 0.00 0.0063
2024-04-30 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,725 -75 -4.17 238 0.00 0.0063
2024-02-05 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,800 -1,525 -45.86 237 -36.63 0.0077
2023-10-24 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,325 0 0.00 374 19.49 0.0139
2023-08-04 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,325 0 0.00 314 -6.85 0.0118
2023-04-07 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,325 0 0.00 337 -15.37 0.0141
2023-02-02 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,325 10 0.30 397 12.78 0.0190
2022-10-12 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,315 0 0.00 352 8.98 0.0186
2022-07-27 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,315 0 0.00 323 3.86 0.0170
2022-04-25 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,315 0 0.00 311 10.28 0.0144
2022-02-11 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,315 0 0.00 282 -11.32 0.0127
2021-11-05 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,315 0 0.00 318 -1.55 0.0162
2021-08-10 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,315 0 0.00 323 0.31 0.0171
2021-05-10 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,315 -1,204 -26.64 322 -25.64 0.0187
2021-01-19 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,519 0 0.00 433 -0.46 0.0271
2020-10-16 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,519 -1,205 -21.05 435 -37.68 0.0326
2020-08-03 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,724 2,309 67.61 698 135.81 0.0602
2020-04-27 2020-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 3,415 -12,045 -77.91 296 -82.19 0.0327
2020-04-10 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,415 -12,045 296 32,830.1594
2020-01-21 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,460 5,088 49.06 1,662 77.75 0.1598
2019-10-16 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 10,372 -2,500 -19.42 935 -13.98 0.0999
2019-08-09 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,872 -12,746 -49.75 1,087 -51.84 0.1218
2019-05-14 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 25,618 12,784 99.61 2,257 146.40 0.2620
2019-02-07 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,834 12,834 916 0.1194
2018-08-08 2018-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -2,625 -100.00 0 -100.00
2018-05-04 2018-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,625 0 0.00 218 6.86 0.0352
2018-02-09 2017-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,625 2,625 204 0.0349
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.